Second-line Treatment of Advanced Non-small Cell Lung Cancer Non-oncogene Addicted: New Treatment Algorithm in the Era of Novel Immunotherapy

Title:Second-line Treatment of Advanced Non-small Cell Lung Cancer Non-oncogene Addicted: New Treatment Algorithm in the Era of Novel Immunotherapy

Volume: 13 Issue: 2

Author(s): Cesare Gridelli*, Paolo Antonio Ascierto, Francesco Grossi, Editta Baldini, Adolfo Favaretto, Maria Chiara Garassino, Alessandro Morabito, Maria Rita Migliorino, Antonio Rossi and Filippo de Marinis

Affiliation:

• Division of Medical Oncology, "S. G. Moscati" Hospital, Avellino,Italy

Keywords: Antiangiogenetics, chemotherapy, immunotherapy, non-small cell lung cancer, second- line treatment, epidermal growth factor receptor.

Abstract: Background: Most patients with advanced non-small cell lung cancer (NSCLC) have a poor prognosis and receive limited benefit from conventional treatments, especially in later lines of therapy. In recent years, several novel therapies have been approved for second- and third-line treatment of advanced NSCLC beyond old chemotherapy agents (docetaxel and pemetrexed) and the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKI, erlotinib). In particular, the new antiangiogenetics (nindetanib and ramucirumab) in combination with docetaxel and immunotherapy (nivolumab, pembrolizumab and atezolizumab) have been recently approved and represent new treatment options.

Methods: The Italian Association of Thoracic Oncology (AIOT) organized five meetings in different Italian regions representing North, Middle and South of the country in order to discuss the issue.

Results: In light of these new approvals, it is valuable to understand the uptake of these new therapies in routine clinical practice and their impact on patient care. With these treatment options to define an appropriate algorythm is object of debate.

Conclusion: The present paper discusses the old and new treatment opportunities, proposing a shared algorithm for second-line setting in advanced NSCLC.

Cite this article as:

Gridelli Cesare*, Ascierto Antonio Paolo , Grossi Francesco , Baldini Editta , Favaretto Adolfo, Garassino Chiara Maria , Morabito Alessandro , Migliorino Rita Maria , Rossi Antonio and de Marinis Filippo , Second-line Treatment of Advanced Non-small Cell Lung Cancer Non-oncogene Addicted: New Treatment Algorithm in the Era of Novel Immunotherapy, Current Clinical Pharmacology 2018; 13 (2) . https://dx.doi.org/10.2174/1574884713666180711160008